The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

Wed, 31st Jan 2024 08:55

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

The FTSE 100 index opened up 2.76 points at 7,669.07. The FTSE 250 was down 11.48 points at 19,338.02, and the AIM All-Share was down 0.19 of a points at 754.70.

The Cboe UK 100 was down 0.1% at 765.96, the Cboe UK 250 was down 0.1% at 16,798.28, and the Cboe Small Companies was down 0.1% at 14,733.78.

In the US on Tuesday, Wall Street ended mixed, as investors looked ahead to Wednesday's interest rate decision. The Dow Jones Industrial Average was up 0.4%, whilst the S&P 500 was down 0.1% and the Nasdaq Composite was down 0.8%.

On Wednesday, all eyes will be on the latest interest rate decision from the US. The Fed will announce its latest decision at 1900 GMT.

It is expected to leave the federal funds rate range unmoved at 5.25% to 5.50%. What happens next has markets divided, however.

According to the CME FedWatch Tool, there is a 45% chance the central bank cuts rates in the following meeting in March. That probability stood at 73% a month ago.

Focus on Wednesday will be on whether the Fed Chair Jerome Powell offers any clues on the interest rate outlook.

Eyes will then swiftly turn onto the Bank of England, which will announce its latest interest rate decision at 1200 GMT on Thursday. Like the Fed, the BoE is expected to keep rates unchanged.

In early economic news, UK house prices edged higher in January, according to Nationwide.

The Nationwide house price index showed a 0.7% increase in seasonally-adjusted UK house prices in January, after showing no change in December. According to FXStreet, market consensus expected the house price index to edge up 0.1% on-month.

In January, the average UK house price stood at GBP257,656, up slightly from GBP257,443 in December, without seasonal adjustment.

Annually, the house price index edged down 0.2%, slowing from a 1.8% decline in December. This came in lower than consensus, with markets pencilling in a 0.9% fell.

"There have been some encouraging signs for potential buyers recently with mortgage rates continuing to trend down. This follows a shift in view amongst investors around the future path of Bank Rate, with investors becoming more optimistic that the Bank of England will lower rates in the years ahead," said Robert Gardner, Nationwide's chief economist.

On the back of the data, housebuilders were trading higher. Taylor Wimpey jumped 1.0%, Barratt Developments rose 0.4% and Persimmon edged up 0.3%.

Elsewhere in the FTSE 100, GSK fell 0.4% as it announced a lower total dividend for 2023.

GSK reported that turnover in 2023 rose 3.4% to GBP30.33 billion from GBP29.32 billion a year earlier.

Notably, GSK reported GBP1.24 billion in revenue for its respiratory syncytial virus vaccine Arexvy, which received approval in the US, the EU, Japan, the UK and Canada in 2023.

Pretax profit in the year climbed 7.7% to GBP6.06 billion from GBP5.63 billion.

On the back of the results, the pharmaceutical company paid out a dividend of 16p, bringing the full year dividend to 58p, which was 5.3% lower than a total payout of 61.25p in 2022.

Looking ahead, GSK said it expects turnover growth between 5% and 7% in 2024. It expects to pay a dividend of 60p per share.

Chief Executive Emma Walmsley said: "GSK delivered excellent performance in 2023, with clear highlights being the exceptional launch of Arexvy and continued progress in our pipeline. We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology."

In the FTSE 250, Harbour Energy lost 4.5%.

Goldman cut its stock to 'sell' from 'buy'.

Other FTSE 250 stocks were also hurt by stock broker cuts.

Morgan Advanced lost 2.5% and Victrex fell 1.8%. Both companies saw a rating cut by Jefferies.

Meanwhile, FDM lost 1.9% on the back of a trading update.

The IT-focused professional services provider expects its financial performance to be in line with expectations. Revenue for the year is expected to edge up to GBP334 million up from GBP330 million a year earlier.

"The last nine months of 2023 saw difficult trading conditions across our markets, with many clients delaying and deferring decisions around projects and consultant placements given the macro-economic and geo-political uncertainties they faced. Our agile business model allowed us to take the action required to align our business activity and resources appropriately, a programme which continues into the current year," said CEO Rod Flavell.

On AIM, Pebble Beach jumped 30%.

The company said its 2023 trading performance was ahead of market forecasts, with revenue up to GBP12.4 million from GBP11.2 million a year earlier.

he revenue generated by Pebble Beach includes recurring revenue of approximately GBP5.2 million up 13% from GBP4.6 million.

In Asia on Wednesday, the Nikkei 225 index in Tokyo was up 0.6%. In China, the Shanghai Composite was down 1.5%, while the Hang Seng index in Hong Kong was down 1.4%. The S&P/ASX 200 in Sydney closed up 1.1%.

In European equities on Wednesday, the CAC 40 in Paris was up 0.3%, while the DAX 40 in Frankfurt was up 0.1%.

The pound was quoted at USD1.2695 early on Wednesday in London, higher compared to USD1.2665 at the equities close on Tuesday. The euro stood at USD1.0823, down against USD1.0839. Against the yen, the dollar was trading at JPY147.43, down compared to JPY147.80.

Brent oil was quoted at USD82.14 a barrel early in London on Wednesday, down from USD82.32 late Tuesday. Gold was quoted at USD2,040.19 an ounce, higher against USD2,033.15.

Still to come on Wednesday's economic calendar, there is German consumer price inflation data.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.